However, several trials (e.g. TRIBUTE, TALENT, INTACT) have failed to show a benefit to small molecule EGFR inhibitors in combination with chemotherapy in NSCLC (reviewed in [48]). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.